摘要
目的评价甘氨双唑钠(CMNa)对中晚期食管癌放射增敏作用的近期疗效和不良反应。方法140例初诊为食管癌(T3-4N0-2M0)的患者随机分为CMNa+放疗组(增敏组)和单纯常规放疗组(单放组)(以下相同),两组放射治疗方法、设野、剂量相同。增敏组患者于放疗前1h内应用CMNa 800mg/m2,静脉注射,每周3次,贯穿放疗全程。结果两组患者的临床资料具有可比性。两组疗效达到CR、PR时放射增敏比分别为0.80(56Gy/70GY)和0.72(42Gy/58Gy),差异有统计学意义(P<0.05)。近期疗效方面,增敏组CR达57.1%(40/70),单放组CR为35.7%(25/70),差异有统计学意义(P<0.05):CR+PR两组分别为97.1%和87.1%,差异无统计学意义(P>0.05)。两组患者仅有少数病例出现轻、中度的放射性食管粘膜反应,无明显的心、肝、肾、神经毒性。结论CMNa能提高中晚期(T3-4N0-2M0)食管癌患者的CR,放射增敏作用明显;安全性好,无明显不良反应。
Objective To evaluate the effect and toxicity of Glycochotic CMNa for adyanced esophageal cancer radiation sensitivity. Methods Total 140 cases of newly diagnosed for esophageal cancer（T3-4N0-2M0） of the patients were randomly divided into CMNa^＋ radiotherapy group（ sensitizer）, and simple conventional radiotherapy alone（ control gronp） （hereinafter the same）, two radiation treatments, the same dose. Enhancement in an hour before radiotherapy application CMNa800 mg/m^2, intravenous drip three times a week. Radiotherapy throughout the entire process. Results The therapeutic effect achieved CR, PR radiation sensitizer are the ratio of 0. 80 （56Gy/70Gy）, and 0. 72 （42Gy/ 58Gy ）, the difference was statistically significant （P 〈 0.05 ） . Recent efficacy, CR enhancement group reached 57. 1% （40/70）, CR alone group to 35.7% （25/70）, the difference was statistically significant（ P 〈0.05） ;CR＋PR the difference was not statistically significant（ P 〉0.05）. Two groups only a small number of cases showed mild to moderate esophageal mucosa radioactive reaction no obvious heart,liver,kidney neurotoxicity. Conclusion CMNa can enhance advanced（T3-4N0-2M0） CR of the： patients with esophageal cancer, radiation sensitivity ; safe, with no obvious toxicity.
出处
《医药论坛杂志》
2008年第2期58-59,61,共3页
Journal of Medical Forum
关键词
食管肿瘤
甘氨双唑钠
放射增敏剂
Esophageal cancer
Liang - sodium
Radiotherapy synergist
